

EBMT 2026

52nd Annual Meeting of the EBMT

March 22–25, 2026
Madrid, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.

EBMT 2026: Top abstracts in GvHD

March 22–25, 2026

Oral presentations: Monday, March 23

Abstract	Title	Presenter	Time (CET)
GS2-8 View	MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Final results from the ARES phase III trial	Florent Malard	17:33–17:42

Oral presentations: Tuesday, March 24

Abstract	Title	Presenter	Time (CET)
OS11-03 View	T cell resistance to glucocorticoids in graft-versus-host disease	Andrew McIntyre	11:18–11:27
OS12-07 View	Post-transplant cyclophosphamide dose reduction within an entirely calcineurin and mTOR inhibitor-free GvHD prophylaxis regimen: Interim results of the ABC phase I-IIb trial	A Samer Al-Homsi	15:24–15:33
Paed3-07 View	Real-world outcomes of mesenchymal stromal cell therapy in heavily pre-treated paediatric patients with refractory acute graft-versus-host disease	Peter Bader	15:24–15:33

Oral presentations: Wednesday, March 25

Abstract	Title	Presenter	Time (CET)
OS14-01 View	Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allo-HSCT plus Tac/Mtx for GvHD prevention in randomized phase 3 clinical trial (Precision-T)	Arpita Gandhi	08:30–08:39
OS16-01 View	Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety	Jianyun Liao	12:30–12:39
OS16-04 View	Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Updated safety analysis of a randomized, phase 2 study	Amandeep Salhotra	12:57–13:06
OS16-05 View	Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GvHD: Update from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP	Udo Holtick	13:06–13:15
OS16-06 View	A comprehensive analysis of axatilimab in patients with chronic graft-versus-host disease and related bronchiolitis obliterans syndrome: Integrated analysis from 2 clinical studies	Zachariah DeFilipp	13:15–13:24
OS16-07 View	Chronic graft-versus-host disease: Real-world outcomes and efficacy of ruxolitinib compared with conventional treatments	Thomas Sau Yan Chan	13:24–13:33

Posters			
Abstract	Title	Presenter	Date and time (CET)
B005 View	Key results from the CHRONOS multicentre retrospective cohort study describing patient outcomes in third-line acute gastrointestinal GvHD	Johannes Clausen	Sunday, March 22, 08:30–18:00
B006 View	Phase 2 study of extracorporeal photopheresis with [methoxsalen] plus standard steroid treatment for high-risk acute graft-versus-host disease	Francis Ayuketang Ayuk	Sunday, March 22, 08:30–18:00
B007 View	Clinical outcomes among patients with chronic graft-versus-host disease treated with axatilimab: Analysis of an expanded access program	Anthony Stein	Sunday, March 22, 08:30–18:00
B016 View	The combination of ruxolitinib and extracorporeal photopheresis is a highly effective second line treatment for chronic graft-versus-host disease	Nikolett Wohner	Sunday, March 22, 08:30–18:00
B018 View	Mesenchymal stromal cells for the treatment steroid refractory graft-versus-host disease in children	Krzysztof Czyzewski	Sunday, March 22, 08:30–18:00
B033 View	Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study	María Sola Soto	Sunday, March 22, 08:30–18:00
B048 View	Efficacy and safety of belumosudil-ECP (extracorporeal photopheresis) combination therapy in refractory chronic graft-versus-host disease (cGvHD) and correlation with cytokin kinetic: A single-center retrospective study	Chiusolo Patrizia	Sunday, March 22, 08:30–18:00
B055 View	Real-world efficacy and toxicity profile of ruxolitinib in pediatric acute and chronic graft-versus-host disease: A multicenter retrospective study	Andrea Buonsante	Sunday, March 22, 08:30–18:00
P123 View	Faecal microbial transplantation for graft-versus-host disease	Andrea Henden	Sunday, March 22, 08:30–18:00
P128 View	Etanercept as second-line therapy for steroid-refractory GvHD: Feasibility, safety, and outcomes	Michel Lu	Sunday, March 22, 08:30–18:00
P131 View	ECP based combinations for treating acute and chronic graft versus host disease	Simon Bulley	Sunday, March 22, 08:30–18:00



#EBMT26

Follow us on X to keep up to date
with the latest from the congress

@GvHD_Hub



Brought to you by

